Microglia in Tauopathy: Not Just Homeostatic Versus DAM
In mouse models of tauopathy, microglia populations are far from binary. Different activation stages emerge at different phases of disease, some marked by viral defense pathways.
ALL NEWS
5723 RESULTS
Sort By:
- Most Recent
- Most Commented
Biogen Asks FDA To Approve Aducanumab
New drug application is first for Alzheimer’s disease in the U.S. since 2003, and first based on amyloid hypothesis.
Seeing into the Human Synapse: New Tools Illuminate Alzheimer’s Hot Spot
New synaptic profiling and imaging techniques are enabling scientists to zero in on synaptic proteins, including phospho-tau, that make the difference between clinical Alzheimer’s and resilience.
You Are What You Breathe: Polluted Air Tied to Plaques, Brain Atrophy
Two cohorts—IDEAS and WHIMS—show Aβ accumulation and brain shrinkage in cognitively normal and impaired elderly who were exposed to levels of air pollution even within current EPA limits.
Trials of Diabetes-Related Therapies: Mainly a Bust
At CTAD, intranasal insulin trial stumbles, pioglitazone gets a postmortem, a RAGE inhibitor tries to hang on.
MTBR-243 Tau: A Fluid Biomarker for Tangles Themselves?
Researchers found that bits of tau from the protein’s microtubule-binding region can be detected in the cerebrospinal fluid. These, not phospho-tau or total tau, reflect neurofibrillary tangles in the Alzheimer’s brain.
Positive Phase 2 Results Claimed for Masitinib in Alzheimer’s
Topline results suggested that the anti-inflammatory treatment stabilized cognition and function over six months. The trial did not include biomarkers.
Begone 2020: Despite COVID, Alzheimer’s Research Advanced
Confronting unprecedented challenges this past year, scientists found ways to tide their research over and keep clinical trials mostly on track.
Does TYROBP-ApoE Signaling Work Independently of TREM2?
This pathway may transmogrify microglia during neurodegeneration, without the help of TREM2.
Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
The Mega-Appeal of Nanomedicine
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD ...
Proteomics Uncovers Potential Markers, Subtypes of Alzheimer’s
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.
Guidelines Bring Needed Change, Though Not Enough for Some
U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage. ...
Modern Microscopy
Modern Microscopy Skims Surface of Living Minds and Spines Modern Microscopy Plumbs the Depths of Brain Tissue ...
New Genetics—From Sequence to Knowledge
When the first human genome sequence was finished in 2003, it quickly became clear that its seemingly unending stream of letters was not enough to comprehend what makes people tick. All the moving parts that bring the DNA code to life needed to be ...
Current Filters
- Date Range : All x